Phase 2 cohort-2 trial in progress: Vabametkib plus lazertinib for patients with EGFR-mutant NSCLC who developed resistance to 1st-line, 3rd-gen-EGFR TKIs via C-Met dysregulation.

Rybrevant (amivantamab-vmjw) - J&J

Lazcluze (lazertinib) - J&J

vabametkib (ABN401) - Abion

Dae Ho Lee; Hye Ryun Kim; Hanlim Moon; Inyoung Kim; Nirmal Rajasekaran; Sunyhe Im; Na Young Kim; Jun Young Choi; Youngkee Shin; Se-Hoon Lee

Apr 23, 2025